WASHINGTON, April 25, 2016 /PRNewswire/ -- On Wednesday, ITI Chief Executive Officer Bill Hearl, PhD will deliver the closing keynote remarks at the third annual Wharton DC Innovation Summit. His talk is titled "From Innovation to ROI: A Biotech Success Story" and will focus on ITI's unique investment strategy and how the company developed an innovative vaccine technology from Johns Hopkins and turned it into a $300 million cash licensing deal and delivered a five-fold return for its investors.
"I am pleased to participate in the esteemed Wharton DC Innovation conference and share what I've learned about licensing new vaccine technology through a limited investment model," said ITI Chief Executive Officer Bill Hearl, PhD. "Replicating our regional market approach could secure new possibilities for important medical developments like the LAMP-Vax technology platform, which has the potential revolutionize vaccine efficacy through immune system re-education."
The Third Annual Wharton Innovation Summit, Raise Your Innovation IQ, is a two-day event taking place Tues., April 26 – Wed., April 27 at FHI 360 located at 1825 Connecticut Avenue NW in Washington, D.C.
Additional speakers include author Chris Surdak discussing Big Data, Susan Dentzer (NEHI) talking about healthcare's tough new issues, Google's Gopi Kallayil sharing new venture lessons and the "Fathers of the Internet," Vint Cerf and Bob Kahn, co-inventors of the key internet protocol, sharing what they know about the future internet challenges.
Follow the conversation at #WDCInnovation2016
About Immunomic Therapeutics
Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the LAMP-based nucleic acid immunotherapy platforms. These disruptive technologies have the potential to fundamentally improve how we use immunotherapy for cancer, allergies and animal health. Headquartered in Hershey, PA with lab facilities in Rockville, MD, ITI has entered into a significant licensing agreement with Astellas Pharma Inc., to explore the use of LAMP-vax, a next-generation immunotherapy platform, for use to prevent and treat allergic diseases. ITI believes that LAMP-based nucleic acid immunotherapy may have the potential to broaden the current use of cancer immunotherapy. Preclinical data is currently being developed to explore how LAMP nucleic acid constructs could both amplify and activate the immune response in highly immunogenic tumor types and also be used to create robust immune responses to tumor types that otherwise do not provoke an immune response. For information about ITI and LAMP Technology, visit www.immunomix.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/immunomic-therapeutics-iti-delivering-closing-keynote-address-at-wharton-dc-innovation-summit-300256734.html
SOURCE Immunomic Therapeutics, Inc.